UniQure’s Huntington’s gene therapy AMT-130 fails to slow disease progression significantly
UniQure said its gene therapy AMT-130 missed statistical significance on the main goal of slowing Huntington’s disease progression in a four-year analysis, with 44% slowing at 48 months in 12 high-dose patients versus an external control.